

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 2, 2024

---

**Morphic Holding, Inc.**  
(Exact Name of Registrant as Specified in its Charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

001-38940  
(Commission  
File Number)

47-3878772  
(I.R.S. Employer  
Identification No.)

35 Gatehouse Drive, A2  
Waltham, Massachusetts  
(Address of principal executive offices)

02451  
(Zip Code)

Registrant's telephone number, including area code: (781) 996-0955

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	MORF	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**Item 5.02.                   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.**

On January 3, 2024, Morphic Holding, Inc. (the “Company”) announced that Praveen Tipirneni, M.D., the Company’s Chief Executive Officer, has returned to work from his temporary medical leave of absence. Effective as of January 2, 2024, Dr. Tipirneni has resumed his day-to-day operational responsibilities at the Company. In connection with Dr. Tipirneni’s return from leave, Dr. Tipirneni has been reinstated as the Company’s principal executive officer and Bruce N. Rogers, Ph.D., the Company’s President, is no longer the Company’s interim principal executive officer. Dr. Rogers continues to serve as the Company’s President.

A copy of a press release dated January 3, 2024 announcing Dr. Tipirneni’s return has been included as Exhibit 99.1 to this Current Report on Form 8-K but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

---

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press release issued by Morphic Holding, Inc. dated January 3, 2024.</a>
104	The cover page on this Current Report on Form 8-K, formatted in Inline XBRL

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MORPHIC HOLDING, INC.**

Date: January 3, 2024

By: /s/ Marc Schegerin

Marc Schegerin, M.D.

Chief Financial Officer and Chief Operating Officer



### **Morphic to Present at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference**

*-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave-*

**WALTHAM, Mass., Jan. 03, 2024** -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a previously announced temporary medical leave of absence and will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 PM PT/6:45 PM ET. A live webcast of the presentation will be available on the Investor section of Morphic's website at [www.morphictx.com](http://www.morphictx.com). An archived replay will be available on the company's website following the conference.

#### **About Morphic Therapeutic**

Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit [www.morphictx.com](http://www.morphictx.com).

###

#### **Contacts**

Morphic Therapeutic  
Chris Erdman  
[chris.erdman@morphictx.com](mailto:chris.erdman@morphictx.com)  
617.686.1718